Payment overview · 2025
General Payments
$860.32
38 reported records · 12 companies
Healthcare provider profile · identity verified
Holly A Mccormick, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CADIZ, KY · NPI 1346291994
Verified facts
What the public records show
CMS Open Payments records show Holly A Mccormick, APRN received $860.32 in general payments during 2025 across 38 reported records.
Axsome Therapeutics, Inc. accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $238.04 | 27.7% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $199.36 | 23.2% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.00 | 16.3% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $71.47 | 8.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.27 | 7.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.10 | 4.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.35 | 2.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.78 | 2.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.47 | 2.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.44 | 2.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.40 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.64 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $860.32 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $238.04 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $199.36 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $176.13 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $93.00 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $71.47 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.20 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.00 | 5 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $41.10 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.76 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
226 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 478 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 436 | 84 |
| Lisinopril | Lisinopril | 339 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 324 | 62 |
| Omeprazole | Omeprazole | 309 | 72 |
| Gabapentin | Gabapentin | 298 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 281 | 50 |
| Ezetimibe | Ezetimibe | 259 | 52 |
| Metformin Hcl | Metformin Hcl | 231 | 47 |
| Losartan Potassium | Losartan Potassium | 230 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 58 |
| Ozempic | Semaglutide | 226 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 51 |
| Carvedilol | Carvedilol | 211 | 47 |
| Trazodone Hcl | Trazodone Hcl | 211 | 45 |
| Montelukast Sodium | Montelukast Sodium | 209 | 32 |
| Simvastatin | Simvastatin | 190 | 49 |
| Furosemide | Furosemide | 186 | 37 |
| Potassium Chloride | Potassium Chloride | 156 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 129 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 25 |
| Aripiprazole | Aripiprazole | 127 | 21 |
| Farxiga | Dapagliflozin Propanediol | 116 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 109 | 17 |
| Fenofibrate | Fenofibrate | 107 | 18 |
| Methylprednisolone | Methylprednisolone | 103 | 68 |
| Buspirone Hcl | Buspirone Hcl | 101 | 20 |
| Tramadol Hcl | Tramadol Hcl | 101 | 20 |
| Clonidine Hcl | Clonidine Hcl | 99 | 27 |
| Fluconazole | Fluconazole | 98 | 56 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 96 | 16 |
| Ibuprofen | Ibuprofen | 95 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 23 |
| Famotidine | Famotidine | 92 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 31 |
| Alendronate Sodium | Alendronate Sodium | 90 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 88 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 26 |
| Eliquis | Apixaban | 81 | 15 |
| Trulicity | Dulaglutide | 81 | 15 |
| Alprazolam | Alprazolam | 80 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 18 |
| Lovastatin | Lovastatin | 73 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 14 |
| Mounjaro | Tirzepatide | 66 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 64 | suppressed |
| Allopurinol | Allopurinol | 63 | 13 |
| Sertraline Hcl | Sertraline Hcl | 62 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 15 |
| Meloxicam | Meloxicam | 57 | 15 |
| Amoxicillin | Amoxicillin | 56 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 13 |
| Pregabalin | Pregabalin | 52 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Spironolactone | Spironolactone | 48 | 14 |
| Donepezil Hcl | Donepezil Hcl | 47 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 47 | 44 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 36 |
| Celecoxib | Celecoxib | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 34 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 45 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 11 |
| Estradiol | Estradiol | 43 | 11 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Temazepam | Temazepam | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 12 |
| Valacyclovir | Valacyclovir Hcl | 37 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 13 |
| Finasteride | Finasteride | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Indapamide | Indapamide | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 29 |
| Meclizine Hcl | Meclizine Hcl | 34 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 34 | 13 |
| Diazepam | Diazepam | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 25 |
| Naproxen | Naproxen | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Cilostazol | Cilostazol | 22 | suppressed |
| Roflumilast | Roflumilast | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 13 |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $860.32 · 38 records | Axsome Therapeutics, Inc. | AIRSUPRA, Auvelity, CAPLYTA, FANAPT, GVOKE HYPOPEN, Kerendia, LEQVIO, NEXLETOL, OTEZLA, QULIPTA, REPATHA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error